GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement

Gilead will make an upfront payment of $1.25 billion to ViiV Healthcare in the first quarter of 2022